Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study

Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study

BackgroundImmunotherapy has become a powerful clinical strategy for treating recurrent or metastatic cervical cancer (R/M CC). Cadonilimab, a novel anti-PD-1/CTLA-4 bispecific antibody, has shown substantial clinical benefits in cancer treatment. However, there is no real-world evidence of cadonilim...

Full description

Saved in:
Bibliographic Details
Main Authors: Jian Chen, Haijuan Yu, Yingtao Lin, Dan Hu, Li Liu, Renliang Fan, Jianping Zou, Lele Zang, Yao Lin, Rong Lin, Dezhao Chen, Xiaoying Weng, Fenfang Shen, Shaoyu Wang, Wei Zeng, Qihua Tian, Yun Yi, Yuanfeng Chen, Jinjin Miao, Bo Zhang, Yinxia Zou, Fengming Gao, Rong Lian, Lin Yang, Yang Sun
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Immunology
Subjects:
recurrent or metastatic cervical cancer
PD-1
CTLA-4
bi-specific antibody
cadonilimab
real world
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1611696/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1611696/full

Similar Items